United Therapeutics | UTHR - Current Liabilities


United Therapeutics reported $599.1M in Current Liabilities for its fiscal quarter ending in March of 2026.





Current Liabilities Change Date
Amarin USD 179.64M 14.82M Mar/2026
Ardelyx USD 109.57M 20.96M Mar/2026
Baxter International USD 3.69B 723M Mar/2026
Bayer EUR 33.46B 875M Mar/2026
BioCryst Pharmaceuticals USD 195.39M 675K Mar/2026
Biogen USD 3B 350.5M Mar/2026
BioMarin Pharmaceutical USD 793.15M 34.12M Mar/2026
Emergent BioSolutions USD 651.3M 12.7M Dec/2023
Esperion Therapeutics USD 300.36M 451K Mar/2026
Gilead Sciences USD 9.48B 2.34B Mar/2026
GlaxoSmithKline GBP 22.43B 1.04B Mar/2026
Halozyme Therapeutics USD 363.21M 186.12M Mar/2026
Insmed USD 361.01M 107.87M Mar/2026
Ionis Pharmaceuticals USD 717M 66M Mar/2026
J&J USD 57.72B 3.59B Mar/2026
Lexicon Pharmaceuticals USD 9.9M 10.97M Mar/2026
Moderna USD 2.4B 408M Mar/2026
Omeros USD 85.5M 2.28M Jun/2025
Pfizer USD 34.35B 2.64B Mar/2026
PTC Therapeutics USD 923.6M 44.82M Mar/2026
Regeneron Pharmaceuticals USD 5.11B 739.3M Mar/2026
Sangamo BioSciences USD 47.66M 1.9M Jun/2025
Sarepta Therapeutics USD 499.16M 596.13M Mar/2026
Teva Pharmaceutical Industries USD 13.53B 76M Mar/2026
United Therapeutics USD 599.1M 38.5M Mar/2026
Vertex Pharmaceuticals USD 3.88B 19.4M Mar/2026